Messersmith, Wells A.

Patient-derived tumour xenografts as models for oncology drug development

Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology

Cancer Cells and MetastasisCancer Genomics and Diagnostics

Cited by 1,277

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 552

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 507

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Meric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., et al. (2022) · Clinical Cancer Research

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 418

A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014

Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research

Alzheimer's disease research and treatmentsWnt/β-catenin signaling in development and cancer

Cited by 218

Current status of SRC inhibitors in solid tumor malignancies

Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist

Cancer Mechanisms and TherapyProtein Kinase Regulation and GTPase Signaling

Cited by 158

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

Arcaroli, J. J., Touban, B. M., Tan, A. C., Varella-Garcia, M., Powell, R. W., Eckhardt, S. G., Elvin, P., Gao, D., & Messersmith, W. A. (2010) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesCancer Mechanisms and Therapy

Cited by 64

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Juric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 59

Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer

Pitts, T. M., Newton, T. P., Bradshaw-Pierce, E. L., Addison, R., Arcaroli, J. J., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Purkey, A., Tentler, J. J., et al. (2014) · PLoS ONE

PI3K/AKT/mTOR signaling in cancerColorectal Cancer Treatments and Studies

Cited by 54

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy

Greene, J., Nguyen, A., Bagby, S. M., Jones, G. N., Tai, W., Quackenbush, K. S., Schreiber, A., Messersmith, W. A., Devaraj, K. M., Blatchford, P., et al. (2017) · Oncotarget

DNA Repair MechanismsCancer therapeutics and mechanisms

Cited by 26

A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)

Scott, A. J., Basu Mallick, A., Dotan, E., Cohen, S. J., Gold, P. J., Hochster, H. S., Subramaniam, S., Barzi, A., Watts, G. S., Blatchford, P. J., et al. (2022) · Cancer Research Communications

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 18

Phase I study of REGN421 (R)/SAR153192, a fully‐human delta‐like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors

Jimeno, A., LoRusso, P., Strother, R. M., Diamond, J. R., Plato, L., Younger, A., Messersmith, W. A., Kittaneh, M., Sawyer, D., Adriaens, L., et al. (2013) · Journal of Clinical Oncology

Angiogenesis and VEGF in CancerCancer Immunotherapy and Biomarkers

Cited by 15